Comparison of next Generation Sequencing Technologies for the Comprehensive Assessment of Full-Length Hepatitis C Viral Genomes

ABSTRACT Affordable next-generation sequencing (NGS) technologies for hepatitis C virus (HCV) may potentially identify both viral genotype and resistance genetic motifs in the era of directly acting antiviral (DAA) therapies. This study compared the ability of high-throughput NGS methods to generate full-length, deep, HCV sequence data sets and evaluated their utility for diagnostics and clinical assessment. NGS methods using (i) unselected HCV RNA (metagenomics), (ii) preenrichment of HCV RNA by probe capture, and (iii) HCV preamplification by PCR implemented in four United Kingdom centers were compared. Metrics of sequence coverage and depth, quasispecies diversity, and detection of DAA resistance-associated variants (RAVs), mixed HCV genotypes, and other coinfections were compared using a panel of samples with different viral loads, genotypes, and mixed HCV genotypes/subtypes [geno(sub)types]. Each NGS method generated near-complete genome sequences from more than 90% of samples. Enrichment methods and PCR preamplification generated greater sequence depth and were more effective for samples with low viral loads. All NGS methodologies accurately identified mixed HCV genotype infections. Consensus sequences generated by different NGS methods were generally concordant, and majority RAVs were consistently detected. However, methods differed in their ability to detect minor populations of RAVs. Metagenomic methods identified human pegivirus coinfections. NGS provided a rapid, inexpensive method for generating whole HCV genomes to define infecting genotypes, RAVs, comprehensive viral strain analysis, and quasispecies diversity. Enrichment methods are particularly suited for high-throughput analysis while providing the genotype and information on potential DAA resistance.

[1]  Christopher Ruis,et al.  Norovirus Whole-Genome Sequencing by SureSelect Target Enrichment: a Robust and Sensitive Method , 2016, Journal of Clinical Microbiology.

[2]  J. Rockstroh,et al.  Simeprevir with pegylated interferon alfa 2a plus ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a meta-analysis and historical comparison , 2015, BMC Infectious Diseases.

[3]  M. Imamura,et al.  Long term persistence of NS5A inhibitor‐resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy , 2015, Journal of medical virology.

[4]  David Bonsall,et al.  ve-SEQ: Robust, unbiased enrichment for streamlined detection and whole-genome sequencing of HCV and other highly diverse pathogens , 2015, F1000Research.

[5]  L. Naeger,et al.  Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir , 2015, Hepatology.

[6]  A. Flaxman,et al.  Global Distribution and Prevalence of Hepatitis C Virus Genotypes , 2014, Hepatology.

[7]  J. Pawlotsky,et al.  EASL Recommendations on Treatment of Hepatitis C 2015. , 2015, Journal of hepatology.

[8]  Oliver Lenz,et al.  Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial , 2014, The Lancet.

[9]  Riina Salupere,et al.  Sofosbuvir and ribavirin in HCV genotypes 2 and 3. , 2014, The New England journal of medicine.

[10]  H. Mo,et al.  Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial , 2014, The Lancet.

[11]  E. Thomson,et al.  Mixed Genotype Hepatitis C Infections and Implications for Treatment , 2014, Hepatology.

[12]  C. Rice,et al.  Expanded Classification of Hepatitis C Virus Into 7 Genotypes and 67 Subtypes: Updated Criteria and Genotype Assignment Web Resource , 2013, Hepatology.

[13]  L. McIntyre,et al.  Consistent Errors in First Strand cDNA Due to Random Hexamer Mispriming , 2013, PloS one.

[14]  T. Hassanein,et al.  Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial , 2013, The Lancet.

[15]  J. V. D. van der Meer,et al.  Alarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSM , 2011, AIDS.

[16]  P. Klenerman,et al.  Dynamic coinfection with multiple viral subtypes in acute hepatitis C. , 2010, The Journal of infectious diseases.

[17]  P. Klapper,et al.  Planning for the healthcare burden of hepatitis C infection: Hepatitis C genotypes identified in England, 2002-2007. , 2010, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[18]  H. Blum,et al.  [Molecular virology of hepatitis C]. , 2002, Praxis.

[19]  A. Creutzig,et al.  [Clinical evidence]. , 2001, VASA. Zeitschrift fur Gefasskrankheiten.

[20]  M. Major,et al.  The molecular virology of hepatitis C , 1997, Hepatology.

[21]  A. Weiner,et al.  Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution , 1992, Journal of virology.